sdAb Humanization
Creative Biolabs is a leading service provider in the field of sdAb development and downstream engineering. Based on our extensive experience of sdAb humanization, our scientists provide the best-fit solutions to generate novel humanized sdAbs for our customers all over the world.
Due to the small size, excellent stability, high affinity, and improved solubility, sdAbs binding selectively to the specific antigen have presented great potential for biotechnological and medical applications, especially for molecular imaging or therapeutic purposes. While, although camelid sdAbs reveal high sequence similarity with human family III VH, the immunogenicity raised from non-human origin is still a big concern in therapeutic applications. Therefore, sdAb humanization is still a precondition for therapeutic sdAb drug candidates to enter the clinical stages.
To satisfy this practical need from our clients, Creative Biolabs has developed a novel HuSdL™ humanization platform that can almost eliminate the immunogenicity of a sdAb to humans while retaining its specificity and affinity. Compared with conventional sdAb humanization strategies, our HuSdL™ platform can better avoid various risks caused by immunogenicity in clinical.
Advantage of HuSdL™ sdAb
- Smallest antibody fragment with high affinity and high specificity
- Hardly immunogenic to humans
- Effective human therapeutics with reduced risk of side effects and toxicity
- Recognize hidden/cleft epitopes that conventional antibodies cannot
- High stability of reversibly refolding and exist within extreme conditions
- Easily clone and manufacturing with high production yield
HuSdL™ Platform
As an innovative platform for sdAb humanization, HuSdL™ can retain the stability and antigen-binding characteristics of a parental sdAb to the maximum extent possible while reducing its immunogenicity to humans. Moreover, this platform is compatible with other innovative approaches, such as in silico modeling and site-specific optimization.
With the HuSdL™ platform, several features and calculated biophysical property of sdAb can be predicted, including conserved amino acid residues in antibody structures, antigenic sites, and structural properties. Our scientists can then design and develop stable, low-immunogenic sdAb backbone to accommodate the antigen-specific paratopes. A series of strategies are available at Creative Biolabs to allow the epitope specificity of the original sdAb to be retained, especially when specific framework residues were directly or indirectly involved in the antigen interaction. The further screening process will contribute to reducing unacceptable affinity loss and non-functional expression risk. Additionally, we can also help our clients to evolve desired candidates that can adapt to set conditions or present particularly requested characteristics.
Based on our advanced platforms and powerful technologies, Creative Biolabs is confident in offering the best sdAb humanization service to meet the specific needs of the human therapeutic agents with excellent prospects in the clinical stages. If you are interested in sdAb humanization, please feel free to contact us for more details.
Case Study
We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.
Services
